In the study, an HIV-infected individual completed a 12 treatment study of the Aethlon Hemopurifier administered thrice weekly over the course of 30-days. The study was conducted at the Sigma New Life Hospital in Punjab, India. Initial viral load and immune cell data resulting from the study are expected to be available for disclosure in mid-February, 2009.
The Hemopurifier is a therapeutic filtration device that serves as an artificial adjunct to the immune system. In HIV care the Hemopurifier targets the clearance of all circulating strains of infectious HIV, including those varieties that cause patients to fail antiviral drug regimens.
Jim Joyce, chairman and CEO of Aethlon Medical, said: Based on previous treatment outcomes in hepatitis-C patients, we are cautiously optimistic that the data resulting from our first HIV study will also prove to be positive.
The principal investigator of our study has reported all 12 Hemopurifier treatments were completed without any observed adverse events, and that the patient feels an improved sense of well being, including increased energy and appetite.